SOURCE: Greenleaf Medical AB

Greenleaf Medical AB

March 10, 2014 08:10 ET

New Clinical Shows That Greenleaf Medical's Appethyl™ Decreases Urge to Eat Sweet Foods

New Research Presented at Winter Meeting of Society for the Study of Ingestive Behavior

STOCKHOLM, SWEDEN--(Marketwired - Mar 10, 2014) - Since winning the NutrAward for Best New Ingredient at the Nutracon in 2013, Greenleaf Medical AB has continued the research program with their product, Appethyl™, which is a patented and clinically-tested appetite suppression product from spinach. A new clinical on the effects of Appethyl™ suggests that not only is appetite significantly reduced, but also for certain foods. The craving for unhealthy foods such as sweets has now been reported to be significantly reduced by Appethyl™ and linked to the release of GLP-1.

What was known previously was that Appethyl™ suppressed appetite by enhancing CCK release which was a result of temporarily inhibiting the digestion of fat through inhibiting pancreatic lipase. An abstract presented at the Winter Meeting of the Society for the Study of Ingestive Behavior in Switzerland, March 1-6, 2014 summarized these latest findings.

In the study, 36 overweight women aged 40 to 65 years of age were recruited on a weight loss diet intervention for three months. Participants received a daily blueberry shot with or without 5 g of Appethyl™ at breakfast. On the first and last day of the study, blood glucose, insulin and GLP-1 were measured during a period of six hours following breakfast. At the same points in time, the urge for sweet, fat and salt was assessed using Visual Analogue Scale (VAS). Six hours after breakfast, a lunch was served. Thereafter the subjects continued to measure their urge for sweet, fat and salt.

The urge for sweets was significantly suppressed by Appethyl™ after just the first dose (day 1). On the last day of the study this suppression was even stronger and continued throughout the entire day. GLP-1 was not significantly changed on day 1, but on the last day there was a significantly increased release of GLP-1 in subjects taking thylakoids compared to control.

The conclusion of the study was that the suppression of sweet taste may be coupled to the release of GLP-1 and that this release occurs through delaying food digestion as the active components in Appethyl™, known as thylakoids, temporarily inhibit pancreatic lipase for about two hours. These actives have also been shown to slow down the digestion of carbohydrates. A slower rate of food digestion may thus be important for producing efficient release of satiety hormones and suppressed cravings for palatable food.

For more information on Appethyl™ or Greenleaf Medical, please visit or contact Maria Soderberg at +46 70 869 27 06, (GMT +1) email: ms(at)gl-medical(dot)com.

About Greenleaf Medical AB
Greenleaf Medical is a Swedish research and development company, active in the global nutraceutical market, which sells and develops natural ingredients with well-documented, beneficial health effects. Greenleaf Medical works together with universities and international science and regulatory groups. Their products are used in both Functional Food and Dietary Supplements.

Greenleaf Medical believes the secret of health and beauty is based on finding the best ingredients through scientific validation. Dedicated to creating natural products with published mechanism-of-action and efficacy studies, the Greenleaf Medical team believes in the unique composition of natural, active ingredients and innovative formula of their supplements.

Contact Information

  • Contact:

    Elizabeth Maxim
    Media Contact
    Email Contact
    Phone: +1 (310) 994-7381